Abstract
Selective inhibitors of the Src family of protein tyrosine kinases have been developed as therapeutic agents for human tumors, some of which are now in various stages of clinical trial. In this review, recently described novel small molecule ATP-competitive Src inhibitors are discussed, with an emphasis on their potential use as therapeutic inhibitors for advanced-stage malignancies.
Keywords: Src family kinase, Inhibitors, Adenocarcinoma
Mini-Reviews in Medicinal Chemistry
Title: Src Inhibitors as Potential Therapeutic Agents for Human Cancers
Volume: 6 Issue: 6
Author(s): Jose G. Trevino, Justin M. Summy and Gary E. Gallick
Affiliation:
Keywords: Src family kinase, Inhibitors, Adenocarcinoma
Abstract: Selective inhibitors of the Src family of protein tyrosine kinases have been developed as therapeutic agents for human tumors, some of which are now in various stages of clinical trial. In this review, recently described novel small molecule ATP-competitive Src inhibitors are discussed, with an emphasis on their potential use as therapeutic inhibitors for advanced-stage malignancies.
Export Options
About this article
Cite this article as:
Trevino G. Jose, Summy M. Justin and Gallick E. Gary, Src Inhibitors as Potential Therapeutic Agents for Human Cancers, Mini-Reviews in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/138955706777435724
DOI https://dx.doi.org/10.2174/138955706777435724 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interleukin-18: Biology and Role in the Immunotherapy of Cancer
Current Medicinal Chemistry Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies
Current Pharmaceutical Design Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies
Current Medicinal Chemistry Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews β -TrCP Dependency of HIV-1 Vpu-Induced Downregulation of CD4 and BST-2/Tetherin
Current HIV Research Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Cell-Free Technologies for Proteomics and Protein Engineering
Protein & Peptide Letters Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Exploring Protein-Protein Interactions with Synthetic Peptide Arrays
Mini-Reviews in Organic Chemistry Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis
Current Stem Cell Research & Therapy A QSAR Study on a Series of Indolin-2-Ones Acting as Non-Receptor Src Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics Human 90 kDa Heat Shock Protein Hsp90 as a Target for Cancer Therapeutics
Current Chemical Biology Integrin αvβ3 Antagonists for Anti-Angiogenic Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Assessment of Bishosphonate Activity In Vitro
Current Pharmaceutical Design Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets